Severe Asthma Patient Data on Sex Differences in Biologic Treatment Response

Southern Italy Network data from a retrospective analysis of 370 severe asthma patients (235 females, 135 males) treated with biologics. The dataset, authored by figshare admin karger and updated in April 2026, examines sex-related differences in baseline characteristics and predictors of clinical remission at 24 months.

Use Cases

• Modeling predictors of clinical remission based on eosinophil count, FeNO levels, and comorbidities.
• Analyzing sex differences in baseline characteristics like obesity, osteoporosis, smoking history, and nasal polyposis.
• Training classifiers to identify negative predictors of remission, such as OCS-dependency, anxiety, or reflux.
• Conducting comparative effectiveness research for biologics like mepolizumab, benralizumab, and dupilumab.

Strengths

• Includes data for 370 patients with a clear sex distribution (235 females, 135 males).
• Defines a specific clinical outcome (remission) using multiple criteria (no OCS, ACT ≥20, FEV1 >80%, no exacerbations).
• Analyzes multiple biologics (mepolizumab, benralizumab, dupilumab) and includes 24-month follow-up data.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect geographic bias inherent to the Southern Italy Network source.

Provenance

Source

figshare admin karger

Collection Method

Retrospective analysis of patient records from the Southern Italy Network on Severe Asthma Therapy.

Time Range

Treatment and follow-up period up to 24 months; specific collection years not stated.

Freshness

Last updated 2026-04 09:55:09; freshness should be verified.

Geography

Southern Italy